Product delivery in the developing world: Options, opportunities and threats

Haemophilia, Supplement

Volumn 10, Issue 4, 2004, Pages 77-82

  Farrugia, Albert ^a  

^a THERAPEUTIC GOODS ADMINISTRATION   (Australia)

Author keywords

Access; Blood products; Manufacture; Safety; Self sufficiency

Indexed keywords

BLOOD CLOTTING FACTOR; IMMUNOGLOBULIN;

ARTICLE; CONTRACT; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG PURITY; DRUG QUALITY; DRUG SAFETY; FRACTIONATION; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEMOPHILIA; HUMAN; PATIENT COMPLIANCE; PLASMA; PRIORITY JOURNAL;

EID: 11044228081     PISSN: 13550691     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2004.01007.x     Document Type: Article

References (14)

1. Srivastava A. How are the issues defined? In: World Federation of Hemophilia Third Global Forum on the Safety and Safety of Hemophilia Treatment Products. Available at: http://www.wfh.org/Content_Documents/Other_Publications/ Global_Forum_2003.pdf. Last accessed 21 April 2004.
2. Rogoff EG, Guirguis HS, Lipton RA et al. The upward spiral of drug costs: a time series analysis of drugs used in the treatment of hemophilia. Thromb Haemost 2002; 88: 545-53.
3. Farrugia A. Variant Creuzfeldt-Jakob disease and haemophilia - a risk assessment of plasma-derived products. Available at: http://www.wfh.org/Content_Documents/Blood_Safety /vCJD.Bulletin2_revised.pdf Last accessed 5 May 2004.
4. Farrugia A. Plasma for fractionation. Safety and quality issues. Haemophilia 2004; 10: 334-40.
5. Keating LJ. Controversies in transfusion medicine - should donor haemoglobin standards be lowered? Con Transfusion 1989; 29 259-60.
6. Farrugia A. Guide for the assessment of clotting factor concentrates for the treatment of hemophilia. Available at: http://www.wfh.org/Content_Documents/Other_Publications /Reg_Guide_Eng.pdf Last accessed 5 May 2004.
7. Oian K. The status of source plasma in China. Presented to the Third Global Forum on Blood Safety and Sufficiency of the World Federation of Hemophilia, Budapest, September 2003. On http://www.wfh.org/Content_Documents/Other_Publications /Global_Forum_2003.pdf . Accessed last on 24 August 2004.
8. Srivastava A, Chuansumrit A, Chandy M, Duraiswamy G, Karagus C. Management of haemophilia in the developing world. Haemophilia 1998; 4: 474-80.
9. Global Collaboration for Blood Safety - World Health Organisation. Information and Fact Sheet - Plasma Contract Fractionation Program. Available at: http://www.health.gov.au/bt/index.htm.
10. Burnouf T. Domestic and contract plasma fractionation programs. Economical aspects and impacts on local haemophilia care. Presented to the Third Global Forum on Blood Safety and Sufficiency of the World Federation of Hemophilia, Budapest, September 2003.
11. de Oliveira G. Brazilian program of self-sufficiency in blood products. Available at: http://www.who.int/medicines/library/qsm/icdra02/ppt /Plasma_Fraction.ppt Last accessed 5 May 2004.
12. Bird A, Isarangkura P, Almagro D, Gonzaga A, Srivastava A. Factor concentrates for haemophilia in the developing world. Haemophilia 1998; 4: 481-5.
13. Farrugia A. Safety and supply of haemophilia products - wordwide perspectives. Haemophilia 2004; 10: 327-33.
14. Farrugia A. Does the concept of self-sufficiency in blood equal a safety risk for hemophilia patients? Haemophilia; in press.